<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6480">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01824303</url>
  </required_header>
  <id_info>
    <org_study_id>TAR-100-202</org_study_id>
    <nct_id>NCT01824303</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy Study of LiRIS® 400mg in Women With Interstitial Cystitis</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TARIS Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TARIS Biomedical, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the study is to determine if LiRIS®, an investigational drug-delivery
      system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any
      change in IC symptoms following LiRIS administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted in 2 parts: a randomized, blinded part in which subjects are assigned
      randomly (by chance) to LiRIS 400 mg or LiRIS placebo; subjects who complete this part and
      are eligible to continue,may participate in the open-label part in which all subjects
      receive LiRIS 400mg.

      In both parts of the study (blinded and open-label), LiRIS is inserted into the bladder
      during cystoscopy, remains in the bladder for 14 days, and is removed during cystoscopy. In
      addition to the 14 day period with the LiRIS/LiRIS Placebo, there is a screening period of
      up to 2 weeks and a follow up period of 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in subject reported bladder pain on a numerical rating scale</measure>
    <time_frame>Study Days 10 through12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>LiRIS 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LiRIS Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LiRIS 400 mg</intervention_name>
    <description>LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.</description>
    <arm_group_label>LiRIS 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LiRIS Placebo</intervention_name>
    <description>LiRIS Placebo contains lactose, inactive substance.</description>
    <arm_group_label>LiRIS Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Blinded study:

          -  Women age 18 and over

          -  Diagnosed with Interstitial Cystitis as defined by protocol

          -  Able to report IC symptoms of bladder pain, voiding habits, as required by
             protocol, and record in diary

          -  Able to comply with visit schedule and diary completion at home

        Open-label Extension:

          -  Must have completed the blinded study prior to screening for the Open-label extension

        Exclusion Criteria(Blinded and Open-Label Extension):

          -  Pregnant or lactating women

          -  History or presence of any condition that would make it difficult to accurately
             evaluate bladder symptoms

          -  Bladder or urethral abnormality that would prevent safe insertion of investigational
             product

          -  Requiring medication not allowed per study protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Curtis Nickel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University/Kingston General Hospital/Ontario Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Citrus Valley Medical Research , Inc.</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Regan</last_name>
      <phone>626-914-3295</phone>
    </contact>
    <contact_backup>
      <last_name>Robin Metzger</last_name>
      <phone>626-914-3295</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Ramakrishnan</last_name>
      <phone>650-498-4240</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Urological Associates</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonelle Horsely</last_name>
      <phone>386-239-8535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The UrogynecologyCenter, LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209-2002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margo Sanford</last_name>
      <phone>913-307-0044</phone>
      <phone_ext>9</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Female Pelvic Medicine &amp; Urogynecology Institute of MI</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Rogers</last_name>
      <phone>588-616-1135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospitals</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Cooney, RN</last_name>
      <phone>248-551-9477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arthur Smith Institute of Urology</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Johnson, RN</last_name>
      <phone>516-734-8515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Alliance Urology Specialists, PA</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Bennett</last_name>
      <phone>336-232-5322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janet Shuping</last_name>
      <phone>336-716-2612</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Urology Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Mahler</last_name>
      <phone>513-841-7554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna McGrail</last_name>
      <phone>216-778-8432</phone>
    </contact>
    <contact_backup>
      <last_name>Marilyn Alejandro-Rodriquez</last_name>
      <phone>216-778-8432</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Urologic Specialists</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Baiden</last_name>
      <phone>843-449-1010</phone>
      <phone_ext>237</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group, University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Herbert</last_name>
      <phone>865-305-9100</phone>
      <phone_ext>290</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Integrity Medical Research</name>
      <address>
        <city>Mountlake Terrace</city>
        <state>Washington</state>
        <zip>98043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Fierro</last_name>
      <phone>425-275-0680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Exdeo Clinical Research Inc.</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2S 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mavis Ye</last_name>
      <phone>1-604-851-5667</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Applied Urological Research</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Robb</last_name>
      <phone>613 548 7800</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
